Eradicating HIV in infected patients likely requires disrupting the reservoir of infected T cells in the gastrointestinal tract. One way to accomplish this is by targeting cells expressing the α4β7, which has been tested in SIV models and is an approved therapy for inflammatory bowel disease. Uzzan and colleagues studied a small cohort of HIV-infected individuals on antiretroviral therapy that began anti-α4β7 treatment for their mild inflammatory bowel disease.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Adam K.
Contact Adam K., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack